EyeGene Inc. (KOSDAQ:185490)
South Korea · Delayed Price · Currency is KRW 1,480.00
-25.00 (-1.66%)
At close: Jun 5, 2026
EyeGene Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,021 | 3,567 | 3,356 | 3,125 | 5,293 | 3,242 |
Other Revenue | -0 | - | - | -0 | -0 | - |
| 4,021 | 3,567 | 3,356 | 3,125 | 5,293 | 3,242 | |
Revenue Growth (YoY) | 10.16% | 6.29% | 7.37% | -40.96% | 63.27% | -3.61% |
Cost of Revenue | 2,856 | 2,479 | 2,209 | 1,260 | 2,607 | 1,777 |
Gross Profit | 1,165 | 1,088 | 1,147 | 1,865 | 2,687 | 1,465 |
Selling, General & Admin | 4,499 | 4,441 | 5,383 | 7,638 | 9,612 | 7,616 |
Research & Development | 6,985 | 5,922 | 8,266 | 20,363 | 16,343 | 27,994 |
Amortization of Goodwill & Intangibles | 24.43 | 26.72 | 50.6 | 59.59 | 55.68 | 51.76 |
Other Operating Expenses | 114.86 | 112.65 | 165.23 | 372.49 | 358.84 | 398.58 |
Operating Expenses | 12,136 | 11,022 | 14,401 | 28,951 | 26,776 | 36,469 |
Operating Income | -10,970 | -9,935 | -13,254 | -27,086 | -24,089 | -35,004 |
Interest Expense | -628.63 | -628.63 | -699.01 | -462.6 | -395.32 | -1,754 |
Interest & Investment Income | 815 | 815 | 1,468 | 1,891 | 1,579 | 555.89 |
Earnings From Equity Investments | -315.96 | -85.96 | 10.28 | -168.96 | -23.21 | - |
Currency Exchange Gain (Loss) | - | - | -113.95 | -1.66 | -35.85 | - |
Other Non Operating Income (Expenses) | 723.74 | 26.94 | 223.42 | 5,042 | -4,375 | 1,043 |
EBT Excluding Unusual Items | -10,376 | -9,807 | -12,365 | -20,786 | -27,340 | -35,159 |
Gain (Loss) on Sale of Investments | -6,324 | -6,324 | 12.05 | -1,539 | -776.79 | 432.18 |
Gain (Loss) on Sale of Assets | -846.61 | -846.61 | -543.46 | -30.34 | 1.81 | 44.76 |
Asset Writedown | -2,099 | -2,099 | - | -78.18 | - | - |
Other Unusual Items | - | - | - | 2.69 | 457.29 | 29.38 |
Pretax Income | -19,646 | -19,077 | -12,896 | -22,430 | -27,657 | -34,653 |
Income Tax Expense | - | - | - | - | -1,168 | -83.99 |
Earnings From Continuing Operations | -19,646 | -19,077 | -12,896 | -22,430 | -26,489 | -34,569 |
Minority Interest in Earnings | 3,427 | 3,371 | 768.14 | 1,325 | 536.36 | - |
Net Income | -16,219 | -15,706 | -12,128 | -21,106 | -25,953 | -34,569 |
Net Income to Common | -16,219 | -15,706 | -12,128 | -21,106 | -25,953 | -34,569 |
Shares Outstanding (Basic) | 32 | 28 | 27 | 22 | 21 | 18 |
Shares Outstanding (Diluted) | 32 | 28 | 27 | 22 | 21 | 19 |
Shares Change (YoY) | 18.73% | 3.52% | 24.79% | 0.94% | 13.22% | 36.98% |
EPS (Basic) | -506.72 | -561.70 | -449.00 | -975.06 | -1210.28 | -1970.84 |
EPS (Diluted) | -506.72 | -561.70 | -449.00 | -975.06 | -1210.28 | -2053.18 |
Free Cash Flow | -8,570 | -6,084 | -13,685 | -21,506 | -19,336 | -32,382 |
Free Cash Flow Per Share | -267.75 | -217.57 | -506.65 | -993.54 | -901.68 | -1709.67 |
Gross Margin | 28.98% | 30.50% | 34.18% | 59.69% | 50.76% | 45.19% |
Operating Margin | -272.82% | -278.53% | -394.95% | -866.63% | -455.07% | -1079.66% |
Profit Margin | -403.36% | -440.34% | -361.41% | -675.30% | -490.29% | -1066.25% |
Free Cash Flow Margin | -213.13% | -170.57% | -407.82% | -688.10% | -365.27% | -998.79% |
EBITDA | -8,959 | -7,857 | -10,910 | -24,949 | -22,798 | -33,934 |
EBITDA Margin | -222.81% | -220.29% | - | - | - | - |
D&A For EBITDA | 2,011 | 2,077 | 2,343 | 2,137 | 1,291 | 1,070 |
EBIT | -10,970 | -9,935 | -13,254 | -27,086 | -24,089 | -35,004 |
EBIT Margin | -272.82% | -278.53% | - | - | - | - |
Advertising Expenses | - | - | 1.89 | 26.52 | 157.83 | 302.3 |